ACACA and metabolic dysfunction-associated steatotic liver disease: Inhibiting ACC1 by 5-tetradecyloxy-2-furoic acid (TOFA) can completely inhibit hepatic de novo lipogenesis (DNL), which is considered a new strategy for non-alcoholic fatty liver disease (NAFLD) treatment (25).